Cumberland Pharmaceuticals Company Profile (NASDAQ:CPIX)

Analyst Ratings

Consensus Ratings for Cumberland Pharmaceuticals (NASDAQ:CPIX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/10/2016Q116$0.02$8.70 million$7.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415$0.03$29.93 million$8.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$0.04$29.93 million$7.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.09$29.93 million$8.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.09$8.10 million$8.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414$0.10$8.05 million$9.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114$0.02$10.26 million$8.09 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2014Q4 13$0.05($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.04)$7.60 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013$0.02($0.03)$9.40 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q113$0.05$0.05$10.00 million$10.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012$0.14$0.09$13.87 million$13.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312$0.09$0.10$13.05 million$12.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012$0.07$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.05$0.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012$0.05$0.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.06$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011$0.04$0.11ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.03$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2011$0.03$0.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cumberland Pharmaceuticals (NASDAQ:CPIX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Thomas R LawrenceDirectorSell3,000$4.55$13,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Thomas R LawrenceDirectorSell4,000$5.61$22,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Thomas R LawrenceDirectorSell6,000$6.95$41,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Thomas R LawrenceDirectorSell10,000$5.12$51,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Thomas R LawrenceDirectorSell15,000$5.08$76,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Thomas LawrenceDirectorSell20,000$4.54$90,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cumberland Pharmaceuticals (NASDAQ:CPIX)
DateHeadline
07/20/16 11:17 AMETF’s with exposure to Cumberland Pharmaceuticals, Inc. : July 20, 2016 -
07/19/16 09:36 AMShares Trading unchanged at $4.65 Cumberland Pharmaceuticals To…
07/18/16 08:00 AMCumberland Pharmaceuticals To Participate In Avondale Partners' 4th Annual Healthcare Conference - [PR Newswire] - NASHVILLE, Tenn., July 18, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations today announced that management will participate in the 4th Annual Avondale Partners Healthcare 1-1 Conference in Boston. The conference is being held August 10, 2016 at the Boston Harbor Hotel in Boston. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on improving patients' lives through the acquisition, development and commercialization of high-quality meaningful products that improve the quality of care for patients.
06/10/16 07:19 AMCumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors - [at noodls] - NASHVILLE, Tenn., June 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is pleased to announce the addition of Caroline Young to its Board of Directors. Caroline is the prior President ...
05/28/16 05:57 AMLawrence Thomas R, Director of Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) sells 3,000 shares - According to Cumberland Pharmaceuticals Inc's most recent Form 4 filing with the SEC dated May 27 06:04 PM, company Director, Lawrence Thomas R disclosed selling 3,000 shares at a cost of $4.55. At the time of this transaction (May 26), this trade was ...
05/17/16 01:21 PMCumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 03:59 PMCUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition -
05/10/16 05:33 PMEdited Transcript of CPIX earnings conference call or presentation 10-May-16 8:30pm GMT -
05/10/16 04:36 PMCumberland reports 1Q loss -
05/10/16 03:18 PMCumberland Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - NASHVILLE, Tenn., May 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first ...
05/10/16 06:18 AMClinigen Group and Cumberland Pharmaceuticals enter into exclusive U.S. commercialisation agreement for oncology support drug Ethyol® - [at noodls] - Ethyol is an FDA approved cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment ...
05/10/16 06:07 AMQ1 2016 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close -
05/03/16 03:40 PMCumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results - [at noodls] - NASHVILLE, Tenn., May 3, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2016 financial results after the market closes on Tuesday, ...
04/08/16 09:41 AMCumberland Pharmaceuticals Inc (CPIX): Ariel Investments Snapping Up Shares -
02/25/16 03:05 PMCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2015 Financial Results - [PR Newswire] - NASHVILLE, Tenn., Feb. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2015 financial results after the market closes ...
02/10/16 07:30 AMVaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics - [PR Newswire] - NASHVILLE, Tenn., Feb. 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) today announced the publication of an open label multicenter study adding to the growing body of literature that supports Vaprisol® (conivaptan) Injection. The study evaluated both 20 and 40 mg/day doses of conivaptan in hyponatremic patients. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.
02/01/16 05:13 AMCUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
01/25/16 07:27 AMPiramal Critical Care And Cumberland Pharmaceuticals Announce Launch Of Caldolor And Vaprisol Co-Promotion - [at noodls] - and NASHVILLE, Tenn., /PRNewswire/ -- Piramal Critical Care, an integral business unit of (NSE: PEL, BSE: 500302), and (: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, ...
01/17/16 07:05 PMCumberland Pharmaceuticals, Inc. (CPIX) - 23-Nov-15 CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events 20-Nov-15 CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events 18-Nov-15 CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events 9-Nov-15 CUMBERLAND ...
12/21/15 11:23 AMCumberland Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMCUMBERLAND PHARMACEUTICALS INC Financials -
12/07/15 07:30 AMCumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing - [PR Newswire] - Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NEW YORK, Dec. 7, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals ...
11/30/15 08:05 AMCumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 3 - [PR Newswire] - NEW YORK, Nov. 30, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi, Chief Executive Officer, will present live at VirtualInvestorConferences.com on December 3, 2015. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology.
11/24/15 04:23 PMCUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
11/23/15 03:20 PMCaldolor® Launched In Australia For Treatment Of Pain And Fever - [at noodls] - NASHVILLE, Tenn., Nov. 23, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) announced today the launch of Caldolor® in Australia. Caldolor is an intravenous formulation of ibuprofen, approved ...
11/23/15 08:20 AMCaldolor Approved For Use In Pediatric Patients - [PR Newswire] - NASHVILLE, Tenn., Nov. 23, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology announced the approval of Caldolor® (ibuprofen) Injection for pediatric patients six months of age and older. The approval was based on data submitted to the U.S. Food and Drug Administration (FDA) as part of a post-marketing commitment following approval of Caldolor in adults in 2009. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug (NSAID) approved for use in pediatric patients.

Social

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals logoCumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CPIX
  • CUSIP: 23077010
Key Metrics:
  • Previous Close: $4.73
  • 50 Day Moving Average: $4.58
  • 200 Day Moving Average: $4.67
  • P/E Ratio: 259.44
  • P/E Growth: 0.00
  • Market Cap: $75.76M
  • Beta: 1.02
  • Current Year EPS Consensus Estimate: $0.09 EPS
  • Next Year EPS Consensus Estimate: $0.09 EPS
Additional Links:
Cumberland Pharmaceuticals (NASDAQ:CPIX) Chart for Sunday, July, 24, 2016